The September 2026 quarter was a landmark period for Patrys, marked by the commencement of our Phase 1a clinical trial for RLS-2202, our proprietary intravenous formulation of quetiapine being developed as a potential treatment for delirium in acute-care settings. Following HREC approval from Bellberry in late August, we initiated the trial at CMAX in South Australia, and by quarter-end all four Cohort 1 participants had completed dosing, follow-up and their planned clinical assessments. Subsequent to quarter-end, our Safety Review Committee confirmed an acceptable safety and tolerability profile in Cohort 1 and recommended progression to Cohort 2, which will involve 12 healthy volunteers. Final participant dosing for Cohort 2 remains on track for the December 2026 quarter. On the corporate side, we established an international Clinical Advisory Committee comprising leading experts in critical care and delirium research from Australia, the United States and Europe. We also entered a binding agreement with Yale University, securing entitlement to 50% of future commercialisation revenue attributable to our deoxymab intellectual property portfolio, while Yale assumes the majority of future development costs. We closed the quarter with A$2.23 million in cash and anticipate an R&D tax incentive refund of approximately A$620,000 to support ongoing operations. An additional A$160,000 was raised through the completion of Directors' participation in a placement. We welcome any questions you may have about this update or our broader development program.